CytomX Therapeutics (NASDAQ:CTMX) Stock Quotes, Forecast and News Summary

Q: What sector and industry does CytomX Therapeutics (CTMX) operate in?

CytomX Therapeutics is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.

CytomX Therapeutics Stock (NASDAQ: CTMX) stock price, news, charts, stock research, profile.

Open	$1.06
Close	$1.09
Volume / Avg.	1.08M / 1.14M
Day Range	$1.03 - $1.10
52 Wk Range	0.83 - 5.85
Market Cap	$83.50M
P/E Ratio	6.88
Dividend Yield	-
Exchange	NASDAQ
RSI	47
Short Interest	5.65%
Days to Cover	5.63

Recent News

Analysts' Varied Perspectives On CytomX's CX-904 Cancer Study: Safety Profile But Caution in Pancreatic Cancer

Initial data from CytomX Therapeutics' CX-904 Phase 1a study shows safety and anti-cancer activity in heavily pretreated patients with advanced metastatic solid tumors. Reductions observed, especially in pancreatic cancer, with stable disease maintained.

Vandana Singh

Gold Moves Higher; Roblox Issues Weak Outlook

Avi Kapoor

Why Duolingo Shares Are Trading Lower By Around 18%? Here Are Other Stocks Moving In Thursday's Mid-Day Session

Avi Kapoor

Financials

Quarterly

Annual

Name

Revenue Change
Gross Change
EBITDA Change
EBIT Change
Earnings Change

Analyst Trends and Forecast

Jun

Aug

Sep

Nov

Buy

Hold

Sell

Strong Sell

Analyst Rating and Forecast

3.6

Buy

Strong Buy

Buy

Hold

Sell

Strong Sell

Open	$1.06
Close	$1.09
Volume / Avg.	1.08M / 1.14M
Day Range	$1.03 - $1.10
52 Wk Range	0.83 - 5.85
Market Cap	$83.50M
P/E Ratio	6.88
Dividend Yield	-
Exchange	NASDAQ
RSI	47
Short Interest	5.65%
Days to Cover	5.63

Compare

EPS worse than industry

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

EPS worse than industry

FAQ

How do I buy CytomX Therapeutics (CTMX) stock?

You can purchase shares of CytomX Therapeutics (NASDAQ:CTMX) through any online brokerage.

View our list of the best stock brokerages

Who are CytomX Therapeutics (CTMX) competitors?

Other companies in CytomX Therapeutics’s space includes: Skye Bioscience (NASDAQ:SKYE), Anixa Biosciences (NASDAQ:ANIX), bluebird bio (NASDAQ:BLUE), Citius Oncology (NASDAQ:CTOR) and OS Therapies (AMEX:OSTX).

What is the forecast, or price target, for CytomX Therapeutics (CTMX) stock?

CytomX Therapeutics has a consensus price target of $5.70.

What is the current price for CytomX Therapeutics (CTMX)?

The stock price for CytomX Therapeutics (NASDAQ: CTMX) is $1.067 last updated December 20, 2024 at 6:50 PM EST.

Does CytomX Therapeutics (CTMX) pay a dividend?

There are no upcoming dividends for CytomX Therapeutics.

When is CytomX Therapeutics (NASDAQ:CTMX) reporting earnings?

CytomX Therapeutics’s Q4 earnings are confirmed for Monday, March 10, 2025.

Is CytomX Therapeutics (CTMX) going to split?

There is no upcoming split for CytomX Therapeutics.

What sector and industry does CytomX Therapeutics (CTMX) operate in?

CytomX Therapeutics is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.

Comments

CytomX Therapeutics

CytomX Therapeutics (CTMX) Forecast